2616 — CStone Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$7.77bn
- HK$6.36bn
- CNY269.58m
Brief: Cstone Pharmaceuticals To Place Aggregate Of 80 Million Placing Shares
Brief: CStone Pharmaceuticals Announces 2024 Annual Results And Recent Business Progress
Brief: Cstone Pharmaceuticals & Pharmalink Enter Into Strategic Partnership For Sugemalimab
Brief: Cstone Pharmaceuticals Receives MHRA Approval Of Sugemalimab For First-Line Treatment Of Non-Small Cell Lung Cancer In UK
Brief: UK's MHRA Says Sugemalimab Approved To Treat Adult Patients With Non-Small Cell Lung Cancer
Brief: CStone Pharmaceuticals Announces Further Increase In Shareholding By CEO
Brief: CStone Pharmaceuticals Says Patent Publication For CS5006
Brief: CStone Pharmaceuticals Announces Long-Term Survival Data For Cejemly
Brief: Cstone Pharmaceuticals Says Approval Of Manufacturing Localization Registration Application
Brief: CStone Announces European Commission Approval Of Sugemalimab
Brief: Cstone Pharmaceuticals And Hengrui Enter Into Exclusive Promotion Agreement
Brief: Cstone Pharmaceuticals Says Approval For Ayvakit By China NMPA
Brief: Cstone Pharmaceuticals Says CHMP Of European Medicine Agency Recommends Approval Of Cejemly
Brief: CStone Announces European Medicine Agency CHMP Recommends Approval Of Cejemly As First-Line Treatment For NSCLC
Brief: EMA Says Valneva's Chikungunya Vaccine Receives Positive CHMP Opinion
Brief: CStone Pharmaceuticals Says CEO Purchased 3.3 Million Of Co's Shares In Open Market In Six Months
Brief: Cstone Pharmaceuticals Says Acceptance Of RET Inhibitor Gavreto (Pralsetinib) Manufacturing Localization Application
Brief: CStone Pharmaceuticals Says Loss For Year Was RMB367.2 Million
Brief: Cstone Pharmaceuticals Says Fifth Indication Approved For Sugemalimab By China NMPA